pbs_code
stringclasses 390
values | drug
stringclasses 18
values | brand
stringclasses 32
values | formulation
stringclasses 38
values | indication
stringclasses 8
values | treatment_phase
stringclasses 57
values | streamlined_code
float64 9.19k
16.9k
⌀ | online_application
bool 2
classes | authority_method
stringclasses 2
values | hospital_type
stringclasses 3
values | maximum_prescribable_pack
float64 1
5
| maximum_quantity_units
float64 1
180
| number_of_repeats
float64 0
6
| schedule_code
stringdate 2025-07-01 00:00:00
2025-08-01 00:00:00
| schedule_year
int64 2.03k
2.03k
| schedule_month
stringclasses 2
values |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10905Y
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10906B
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
10906B
|
Secukinumab
|
Cosentyx
|
Injection 150 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
10909E
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10909E
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10909E
|
Certolizumab pegol
|
Cimzia
|
Injection 200 mg in 1 mL single use pre-filled syringe
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
10951J
|
Tocilizumab
|
Actemra Subcutaneous Injection
|
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 4 | 3 |
2025-07
| 2,025 |
JULY
|
10951J
|
Tocilizumab
|
Actemra Subcutaneous Injection
|
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 4 | 3 |
2025-07
| 2,025 |
JULY
|
10951J
|
Tocilizumab
|
Actemra Subcutaneous Injection
|
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 4 | 3 |
2025-07
| 2,025 |
JULY
|
10951J
|
Tocilizumab
|
Actemra Subcutaneous Injection
|
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 4 | 3 |
2025-07
| 2,025 |
JULY
|
10954M
|
Tocilizumab
|
Actemra Subcutaneous Injection
|
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 4 | 5 |
2025-07
| 2,025 |
JULY
|
10954M
|
Tocilizumab
|
Actemra Subcutaneous Injection
|
Injection 162 mg in 0.9 mL single use pre-filled syringe
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 4 | 5 |
2025-07
| 2,025 |
JULY
|
11196G
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11196G
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11197H
|
Etanercept
|
Enbrel
|
Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,499 | true |
STREAMLINED
|
Any
| 2 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11198J
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11198J
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11198J
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11198J
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11198J
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11198J
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11201M
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11201M
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11201M
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11202N
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| 16,778 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11202N
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| 16,778 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11204Q
|
Etanercept
|
Enbrel
|
Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 2 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11207W
|
Etanercept
|
Enbrel
|
Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL
|
psoriatic arthritis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 2 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11207W
|
Etanercept
|
Enbrel
|
Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 2 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11208X
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11208X
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11208X
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11208X
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11211C
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,499 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11211C
|
Etanercept
|
Enbrel
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,499 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11215G
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
First continuing treatment
| 14,683 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11215G
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
First continuing treatment
| 14,683 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11215G
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| 14,701 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11215G
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| 14,701 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11216H
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
psoriatic arthritis
|
Subsequent continuing treatment
| 16,778 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11217J
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
ankylosing spondylitis
|
First continuing treatment
| 14,683 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11217J
|
Etanercept
|
Brenzys
|
Injections 50 mg in 1 mL single use pre-filled syringes, 4
|
ankylosing spondylitis
|
Subsequent continuing treatment
| 14,701 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11218K
|
Etanercept
|
Brenzys
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,499 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11218K
|
Etanercept
|
Enbrel
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,499 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11218K
|
Etanercept
|
Nepexto
|
Injection 50 mg in 1 mL single use auto-injector, 4
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,499 | true |
STREAMLINED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11318Q
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
11319R
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11319R
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11319R
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11320T
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11320T
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
ankylosing spondylitis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11321W
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
11322X
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11322X
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11322X
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11323Y
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11323Y
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11323Y
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 3 | 6 | 0 |
2025-07
| 2,025 |
JULY
|
11324B
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11324B
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11325C
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11325C
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 5 |
2025-07
| 2,025 |
JULY
|
11326D
|
Certolizumab pegol
|
Cimzia
|
Solution for injection 200 mg in 1 mL pre-filled pen
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 2 | 2 |
2025-07
| 2,025 |
JULY
|
11361Y
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11361Y
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11361Y
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11361Y
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
ankylosing spondylitis
|
Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11365E
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11365E
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11365E
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
psoriatic arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11365E
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
psoriatic arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11372M
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11372M
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11372M
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11372M
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 3 |
2025-07
| 2,025 |
JULY
|
11373N
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
psoriatic arthritis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11373N
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
psoriatic arthritis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11375Q
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11375Q
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11376R
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
ankylosing spondylitis
|
Continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11376R
|
Golimumab
|
Simponi
|
Injection 50 mg in 0.5 mL single use pre-filled pen
|
ankylosing spondylitis
|
Continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 1 | 5 |
2025-07
| 2,025 |
JULY
|
11437Y
|
Baricitinib
|
Olumiant
|
Tablet 2 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11437Y
|
Baricitinib
|
Olumiant
|
Tablet 2 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11437Y
|
Baricitinib
|
Olumiant
|
Tablet 2 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11437Y
|
Baricitinib
|
Olumiant
|
Tablet 2 mg
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11442F
|
Baricitinib
|
Olumiant
|
Tablet 2 mg
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 5 |
2025-07
| 2,025 |
JULY
|
11442F
|
Baricitinib
|
Olumiant
|
Tablet 2 mg
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 5 |
2025-07
| 2,025 |
JULY
|
11443G
|
Baricitinib
|
Olumiant
|
Tablet 4 mg
|
rheumatoid arthritis
|
First continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 5 |
2025-07
| 2,025 |
JULY
|
11443G
|
Baricitinib
|
Olumiant
|
Tablet 4 mg
|
rheumatoid arthritis
|
First continuing treatment - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 5 |
2025-07
| 2,025 |
JULY
|
11447L
|
Baricitinib
|
Olumiant
|
Tablet 4 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 1 (new patient)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11447L
|
Baricitinib
|
Olumiant
|
Tablet 4 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11447L
|
Baricitinib
|
Olumiant
|
Tablet 4 mg
|
rheumatoid arthritis
|
Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)
| null | false |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11447L
|
Baricitinib
|
Olumiant
|
Tablet 4 mg
|
rheumatoid arthritis
|
Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply
| null | true |
AUTHORITY_REQUIRED
|
Any
| 1 | 28 | 3 |
2025-07
| 2,025 |
JULY
|
11482H
|
Infliximab
|
Inflectra
|
Powder for I.V. infusion 100 mg
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
11482H
|
Infliximab
|
Renflexis
|
Powder for I.V. infusion 100 mg
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
11482H
|
Infliximab
|
Remicade
|
Powder for I.V. infusion 100 mg
|
ankylosing spondylitis
|
Subsequent continuing treatment
| null | false |
AUTHORITY_REQUIRED
|
Public
| 1 | 1 | 0 |
2025-07
| 2,025 |
JULY
|
11483J
|
Infliximab
|
Inflectra
|
Powder for I.V. infusion 100 mg
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,505 | true |
STREAMLINED
|
Private
| 3 | 3 | 2 |
2025-07
| 2,025 |
JULY
|
11483J
|
Infliximab
|
Renflexis
|
Powder for I.V. infusion 100 mg
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,505 | true |
STREAMLINED
|
Private
| 3 | 3 | 2 |
2025-07
| 2,025 |
JULY
|
11483J
|
Infliximab
|
Remicade
|
Powder for I.V. infusion 100 mg
|
rheumatoid arthritis
|
Subsequent continuing treatment
| 14,505 | true |
STREAMLINED
|
Private
| 3 | 3 | 2 |
2025-07
| 2,025 |
JULY
|
11486M
|
Infliximab
|
Inflectra
|
Powder for I.V. infusion 100 mg
|
ankylosing spondylitis
|
First continuing treatment
| 14,683 | true |
STREAMLINED
|
Public
| 5 | 5 | 3 |
2025-07
| 2,025 |
JULY
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.